

Your Partner in SCA Risk Management

Anchored by the **ASSURE® WCD**, the **Cardiac Recovery System®** platform unites proven protection with insights to support recovery



GDMT Takes Time. SCD Doesn't Wait.

The first 90 days after diagnosis carry the highest risk of sudden cardiac death (SCD) in patients with reduced EF ($\leq 35\%$)—leaving a critical gap in protection as GDMT is titrated to full effect.¹

6.5x



higher risk of ventricular arrhythmias in HFrEF patients within initial months of diagnosis compared to stable, chronic patients²

SCD-PROTECT Time to First Appropriate WCD Treatment¹



The Cardiac Recovery System® platform:

- Provides insights that may be helpful in care optimization, including arrhythmia detection (VT/VF, SVT and Bradyarrhythmia) & physiologic trends (heart rate and activity).
- Extends care team's reach through timely clinical alerts & rapid post-shock support.



The Cardiac Recovery System Platform Redefines SCA Risk Management

Designed for Daily Life



With the most customizable fit in the category—seven sizes and two styles—the ASSURE system delivers exceptional comfort and compliance.

- Worn for more than 23 hours per day³
- Up to 87% fewer patients experiencing false alarms than competing WCD patients*^{3,4}

* Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.

Insights to Inform Care



In real-world use, the ASSURE system identified potentially actionable cardiac events^{5,6}:

- Detected arrhythmias in 18% of patients, leading to physician-directed clinical intervention
- Helped identify previously undiagnosed atrial fibrillation in 5.5% of patients with high stroke risk
- Recorded asymptomatic VT in 3.6% of patients, supporting further clinical review for ICD eligibility

An Extension of Your Care Team



Connected services enable timely clinical intervention and patient support.

- Heart Alert™ Services identifies and notifies providers of cardiac events that may warrant action, supporting optimization of care.
- Following a shock, the ASSURE Assist® service is designed to connect patients to the urgent support they need.



Raise the Standard for **SCA Risk Management**



Scan to Take the First Step

¹ Duncker D. et al. *European Heart Journal*. 2025;00:1–10. ² Duncker, D., et al. *Clin Cardiol*. 2017;40(8):586–590. ³ ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS) NCT05135403, Cohort April 2024. ⁴ Arkles, J. et al. *J Interv Card Electrophysiol*. 2023;66(7):1723–1728. ⁵ Phukan A. et al. Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024, Chicago, IL. ⁶ Syed Z. et al. Initial Real-world Experience with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024, Chicago, IL.

©2025 Kestra Medical Technologies, Inc. and its affiliated companies. ASSURE, KESTRA, the Kestra logo, and the Open Heart design, are Registered in the U.S. Patent and Trademark Office. All other product and company names cited herein are marks of their owners.

MKT-00156-01_C

 **kestra**
MEDICAL TECHNOLOGIES

Learn more at kestramedical.com